Clinical data from patients with untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma aged 18-60 years

LHA-ID
7Q0CR2P50P-8
Motivation

Improvement of efficacy of chemotherapy by additional therapy with the monoclonal antibody Rituximab, measured by time to treatment failure

Description

complete clinical data set for the clinical trial

Study Design

Phase-III, multicentre (intergroup)open-label, randomised trial; randomised in CHOP-like regiment with or without Rituximab

Publication Date
Contact
Marita Ziepert
Contact Institution

Institute for Medical Informatics, Statistics and Epidemiology (IMISE)
University of Leipzig
Härtelstr. 16-18
04107 Leipzig

Version Number
1.0
Sample Size
n=824; CHOP-like chemotherapy and rituximab (n=413); CHOP-like chemotherapy alone (n=411)